A new predictive scoring system based on clinical data and computed tomography features for diagnosing EGFR -mutated lung adenocarcinoma

We aimed to develop a new mutation-predictive scoring system to use in screening for -mutated lung adenocarcinomas (lacs). The study enrolled 279 patients with lac, including 121 patients with wild-type tumours and 158 with -mutated tumours. The Student t-test, chi-square test, or Fisher exact test...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current oncology (Toronto) 2018-04, Vol.25 (2), p.e132-138
Hauptverfasser: Cao, Y, Xu, H
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We aimed to develop a new mutation-predictive scoring system to use in screening for -mutated lung adenocarcinomas (lacs). The study enrolled 279 patients with lac, including 121 patients with wild-type tumours and 158 with -mutated tumours. The Student t-test, chi-square test, or Fisher exact test was applied to discriminate clinical and computed tomography (ct) features between the two groups. Using a principal component analysis (pca) model, we derived predictive coefficients for the presence of mutation in lac. The mutation-predictive score includes sex, smoking history, homogeneity, ground-glass opacity (ggo) on imaging, and the presence of pericardial effusion. The pca predictive model took this form: [Formula: see text]Model scores ranged from 79 to 147. The area under the receiver operating characteristic curve was 0.752 [95% confidence interval (ci): 0.697 to 0.801] in the lac population at the optimal cut-off value of 109, and the sensitivity and specificity were 68.4% (95% ci: 60.5% to 75.5%) and 74.4% (95% ci: 65.6% to 81.9%) respectively. The mutation risk scoring system based on clinical data and ct features is noninvasive and user-friendly. The model appears to frame a positive predictive value and was able to determine the value of repeating a biopsy if tissue is limited.
ISSN:1718-7729
1198-0052
1718-7729
DOI:10.3747/co.25.3805